Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 9, 2017, Foundation Medicine, Inc. issued a press release
announcing its financial and operating results for the quarter
ended March 31, 2017. A copy of the press release is being
furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
| 99.1 |
Press release issued by Foundation Medicine, Inc. dated May 9, 2017, furnished hereto. |
About Foundation Medicine, Inc. (NASDAQ:FMI)
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program. Foundation Medicine, Inc. (NASDAQ:FMI) Recent Trading Information
Foundation Medicine, Inc. (NASDAQ:FMI) closed its last trading session up +0.70 at 36.10 with 388,115 shares trading hands.